532523 Stock Overview
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 1/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Biocon Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹271.00 |
| 52 Week High | ₹307.00 |
| 52 Week Low | ₹217.50 |
| Beta | 0.42 |
| 1 Month Change | 7.48% |
| 3 Month Change | 3.10% |
| 1 Year Change | 20.15% |
| 3 Year Change | -31.50% |
| 5 Year Change | -12.55% |
| Change since IPO | 571.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 532523 | IN Biotechs | IN Market | |
|---|---|---|---|
| 7D | 2.1% | -4.3% | -1.6% |
| 1Y | 20.2% | 13.6% | 45.0% |
Return vs Industry: 532523 exceeded the Indian Biotechs industry which returned 13.6% over the past year.
Return vs Market: 532523 underperformed the Indian Market which returned 45% over the past year.
Price Volatility
| 532523 volatility | |
|---|---|
| 532523 Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 532523 has not had significant price volatility in the past 3 months.
Volatility Over Time: 532523's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 16,545 | Siddharth Mittal | www.biocon.com |
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases.
Biocon Limited Fundamentals Summary
| 532523 fundamental statistics | |
|---|---|
| Market cap | ₹323.75b |
| Earnings (TTM) | ₹12.00b |
| Revenue (TTM) | ₹146.13b |
27.0x
P/E Ratio2.2x
P/S RatioIs 532523 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 532523 income statement (TTM) | |
|---|---|
| Revenue | ₹146.13b |
| Cost of Revenue | ₹53.47b |
| Gross Profit | ₹92.66b |
| Other Expenses | ₹80.66b |
| Earnings | ₹12.00b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 16, 2024
| Earnings per share (EPS) | 10.05 |
| Gross Margin | 63.41% |
| Net Profit Margin | 8.21% |
| Debt/Equity Ratio | 75.2% |
How did 532523 perform over the long term?
See historical performance and comparison